We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Delcath’s Rejected Liver Cancer Drug Gets Orphan Designation for New Indication
Delcath’s Rejected Liver Cancer Drug Gets Orphan Designation for New Indication
Oncology drugmaker Delcath Systems has received orphan drug designation for melphalan to treat intrahepatic cholangiocarcinoma, or ICC, a cancer of the bile duct that arises within the liver.